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Background/aim: Congenital heart disease (CHD) is the most common congenital malformation group and is the leading cause of
newborn mortality in developed countries. Most of the infants with CHD develop preoperative or postoperative acute kidney injury
(AKI). Acute kidney injury may develop before the serum creatinine rise and oliguria. Urinary biomarkers such as kidney injury
molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin (IL)-18, and cystatin C may predict AKI in patients
with critical CHD (CCHD) before the serum creatinine rise. In this study, we aimed to determine the AKI incidence among newborn
patients with CCHD and investigate the predictivity of urinary biomarkers for AKI.
Materials and methods: Newborns with a gestational age >34 weeks and birth weight >1500 g with a diagnosis of CCHD were enrolled
in the study. Blood and urine samples were collected at birth, during the first 24–48 h, and in the preoperative and postoperative periods.
Results: A total of 53 CCHD patients requiring surgery during the neonatal period were enrolled in the study. The 24–48 h KIM-1 levels
of the cases with exitus were higher (P = 0.007). The 24–48 h cystatin C and preoperative NGAL levels were higher in patients with
postoperative AKI (P = 0.02).
Conclusion: In newborns with CCHD, high KIM-1 levels may predict mortality, whereas high cystatin C and preoperative NGAL levels
may be indicative of AKI. These biomarkers deserve further investigation in larger study populations.
Key words: Acute kidney injury, cardiovascular surgery, critical congenital heart disease, newborn, urinary biomarker

1. Introduction
Congenital heart disease (CHD) is the most common
congenital malformation in the neonatal period and is a
leading cause of neonatal mortality. Acute kidney injury
(AKI) may develop preoperatively or postoperatively in
neonatal CHD patients. In newborns, oliguria alone is not
sufficiently sensitive to assess renal function and diagnose
renal failure. Furthermore, AKI may develop without
oliguria [1–3]. Therefore, better methods are needed for early
and accurate diagnoses of AKI in newborns [4].
Although the data on the incidence of AKI in newborns
is limited, the reported incidence in neonatal intensive care
units (NICUs) is 8%. Most newborns with AKI are premature
and/or critically ill newborns [5]1. Prerenal renal failure is the
most common etiology (85%) in newborns and may result in
intrinsic kidney failure if it is not treated promptly [6].

The criteria of neonatal RIFLE (risk, injury, failure,
loss of function, end-stage kidney disease) and the Acute
Kidney Injury Network (AKIN) have been established by
modifying the pediatric RIFLE criteria defined in 2007
in order to diagnose AKI in newborns, and an attempt
has been made to standardize the diagnostic criteria
using these standards [1,5]. However, the criteria used
to diagnose AKI in neonates hospitalized in NICUs are
limited in their definition of kidney damage as they are
based on the serum creatinine level and urine volume.
Therefore, the neonatal-modified KDIGO (kidney disease:
improving global outcomes) criteria based on serum
creatinine rise and urine output, in addition to serum
creatinine levels, is commonly used [7,8].
The use of new markers has been increasing due to the
limitations described above. The ideal biomarker should
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be readily available in biological samples (e.g., urine), be
sensitive enough to detect mild renal impairment, have a
high predictive sensitivity for prognosis, and be specific to
acute renal failure (ARF) and independent of glomerular
filtration rate. Acute kidney injury develops in more than
half of the patients with critical congenital heart disease
(CCHD) in the postoperative period [9]. The limitations
of serum creatinine include a lack of steady-state
conditions in critically ill patients and inhibition of timely
management. Early diagnosis and treatment will improve
prognoses and help to create new types of therapeutic
management [5].
To date, there have been a limited number of studies
about urinary biomarkers, especially for predicting AKI in
neonates. Some of the most promising urinary biomarkers
for predicting AKI are cystatin C, IL-18, NGAL, and
KIM-1. These studies of neonates have mostly centered
on specific groups at risk for AKI such as very low birth
weight infants, asphyxiated newborns, and newborns
undergoing major cardiac surgery [5].
In the current study, we aimed to determine the AKI
incidence in infants with CCHD and predict AKI before
the serum creatinine rise by using urinary biomarkers.
2. Materials and methods
Newborns with a gestational age >34 weeks, a birth weight
>1500 g, and a diagnosis of CCHD were followed up in
the NICU of the Ege University Faculty of Medicine and
enrolled in the study. Informed consent was obtained
from all parents of patients who were eligible for the study.
Patients with major malformations other than cardiac
disease; patients with renal anomalies, neonatal sepsis, or
perinatal asphyxia; and cases in which family consent was
not given were excluded. Ethics committee approval for
the study was obtained from the Ege University Medical
Faculty Local Ethics Committee (date: 14.08.2013; no.: 134.1/8).
General supportive care was provided to all patients
according to the NICU protocol. Demographic
characteristics for all newborns were recorded. Blood
samples (2 mL) were collected from the cord, and urine
samples (2 mL) were obtained from the urinary bag during
the first 24 h. In this period, while urine was collected
to determine the possibility of antenatal renal damage,
blood was collected to calculate the creatinine clearance
to account for the maternal effect on creatinine during the
first 24 h of life. Further blood and urine samples were
collected in the first 24–48 h of life, preoperatively, and
24–48 h postoperatively. After 24 h, the blood samples
were collected from the umbilical or central venous
catheter, and the urine samples were collected from the
urine catheter.
All urinary biomarkers were obtained from Shangai
Sunred Biological Technology (China) [catalog numbers:
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201-12-1720 (NGAL), 201-12-1100 (KIM-1), 201-121105 (cystatin C), and 201-12-0148 (IL-18)] and analyzed
by ELISA method. Serum creatinine measurements were
performed spectrophotometrically by the Jaffe method.
Creatinine clearance was calculated using serum creatinine
level and height (centimeters). Neonatal KDIGO staging
was performed to diagnose and evaluate ARF. Neonatal
KDIGO staging is as follows: stage 0, no change in serum
creatinine (SCr) or a rise of 0.3 mg/dL with urine output
>0.5 mL/kg/h; stage 1, SCr rise ≥0.3 mg/dL within 48 h
or SCr rise ≥1.5–1.9 × reference SCr within 7 days with
urine output <0.5 mL/kg/h for 6 to 12 h; stage 2, SCr rise
≥2.0–2.9 × reference SCr with urine output <0.5 mL/kg/h
for ≥12 h; stage 3, SCr rise × 3 reference SCr or SCr level ≥
2.5 mg/dL or receipt of dialysis with urine output <0.3 mL/
kg/h for ≥24 h; stage 4, anuria for ≥12 h.
In our study, group 1 consisted of patients without
acute renal damage, and group 2 was comprised of
patients with acute renal damage developed at any time
during the study period. In patients undergoing surgery,
the presence of cardiopulmonary bypass, hypothermia,
and extracorporeal membrane oxygenation (ECMO), as
well as cross clamping status and duration were recorded.
Neutrophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule (KIM-1), cystatin C, and interleukin (IL)18 levels were examined in the urine. These biomarkers
were examined for every CCHD patient during four
time periods: the first 24 h of life, the first 24–48 h of life,
preoperatively, and 24–48 h after the operation. The levels
of urinary biomarkers of all patients from each of these
time periods were examined and compared according to
AKI development at any stage of the study.
2.1. Statistical analysis
SPSS version 21.0 for Windows (IBM Corp., Armonk, NY,
USA) was used to evaluate the data. Statistical analysis
was performed using the SPSS for Windows statistical
package. The χ2 test was used to compare categorical
variables between groups. The Kolmogorov–Smirnov test
was used to evaluate the normal distribution assumption
for numerical variables. The difference between two
groups was examined by independent samples t-test for
normally distributed variables and the Mann–Whitney
U-test for nonnormally distributed variables. Differences
among more than two groups were examined by ANOVA
with repeated measures. Mauchly’s test of sphericity and
Greenhouse–Geisser corrections were applied to test the
sphericity assumption before ANOVA, with repeated
measures. A paired t-test with the Bonferroni correction
was used for multiple comparisons between tests. In
addition, a paired t-test was used to compare the arithmetic
averages of two independent groups. A P value of <0.05
was considered statistically significant.
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3. Results
The study included a total of 53 newborns requiring major
cardiac surgery due to CCHD. Demographic variables and
the cardiac diagnoses of the patients are summarized in
Table 1.
In our study group, 69.8% of the patients (n = 37)
developed AKI during the study period. In 18 patients
(34%), AKI developed only in the postoperative period.
Among all patients, only one (1.9%) required peritoneal
dialysis during the postoperative period.
The urine specimens and creatinine clearance from 4
different time periods (the first 24 h of life, the first 24–48 h,
preoperative, and 24–48 h postoperative) for each patient
with CCHD were compared. The urinary biomarker levels
are shown in Table 2. The mean values of biomarkers were
also compared to each other for every two time periods;
there was a significant difference between the 24–48 h and
preoperative values of cystatin C (P < 0.05). In addition, the
difference between the 24–48 h and preoperative values of
IL-18 was significant (P < 0.05). In urinary NGAL values,
a significant difference was found between time periods: P
< 0.05 for cord vs. preoperative values and P < 0.05 for 24–
48 h vs. preoperative values. A significant difference was
detected between time periods for urinary KIM-1 values
at 24–48 h vs. preoperative values (P < 0.05). On the other
hand, urinary KIM-1 levels at 24–48 h of life were higher
in patients who were lost during the postoperative period
(P < 0.05).
The most remarkable point was the cystatin C levels at
24–48 h of life; the NGAL levels in the preoperative period
were significantly higher in patients who developed AKI in
the postoperative period (P = 0.02).

The levels of four urinary biomarkers were examined in
all time periods for each patient by grouping the patients
according to presence or absence of AKI. These results are
summarized in Table 3. Urinary IL-18 at 24–48 h of life was
significantly higher in patients developing AKI; however, no
predictive value was detected for postoperative development
of AKI. ECMO was performed on three patients during the
study; only one patient developed AKI, and the damage
started preoperatively. During the study, 13 patients
underwent cardiopulmonary bypass and of these patients,
seven developed AKI (only one case emerged preoperatively).
4. Discussion
Acute renal injury is a frequent clinical complication
observed during the preoperative or postoperative period
in newborns with CCHD. Among the patients in our study,
69.8% developed AKI. Kumar et al. [10] reported an ARF
incidence of 8% in a postoperative period of 72 h among
infants <2 months old. In a study by Alabbas et al. [11], AKI
was detected in 62% of the cardiac patients <28 days old,
which is similar to our study. Acute kidney injury is also
associated with prolonged hospitalization periods and an
increase in mortality. Similarly, Blinder et al. [9] reported
that 225 (52%) of 430 patients younger than 90 days old
developed AKI in the postoperative period. Although
there are various reports about AKI incidence, our results
seem to be compatible with previous reports. In our study,
serum creatinine levels and creatinine clearance were
only significantly higher in the postoperative samples of
patients with AKI. These results highlight the importance
of further studies of urinary biomarkers in order to detect
AKI at earlier stages.

Table 1. Demographic variables of the patients.
n = 53
Gestational age, weeks mean±SD (min-max)

38.0 ± 1.7 (34-41)

Birth weight, grams mean ± SD (min-max)

2932 ± 654 (1510-4000)

Term, n (%)
Late preterm, n (%)

43 (81.2)
10 (18.8)

Sex, male (%)

33 (62.3)

Cardiac diagnosis, n (%)
Aort coarctation
Transposition of the great arteries
Pulmonary atresia
Tricuspit atresia
Hypoplastic left heart syndrome
Fallot tetralogy
Aort coarctation with transposition of the great arteries
Truncus arteriosus
Double outlet right ventricle with atrioventricular septal defect

14 (26.4)
12 (22.6)
7 (13.2)
7 (13.2)
6 (11.3)
3 (5.7)
2 (3.8)
1 (1.9)
1 (1.9)
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Table 2. Levels of urine examinations of all patients according to time periods.
First 24 h

24-48th h

Preoperative

Postoperative

P*

Cystatin C (ng/mL)

18.19 + 1.06

19.12 ± 0.96

18.20 ± 1.23

20.97 ± 0.79

0.81

IL-18 (ng/mL)

19.40 + 0.86

18.91 ± 0.73

17.19 ± 0.66

18.48 ± 0.78

0.73

NGAL (ng/mL)

314.39 ± 54.20a,b

249.47 ± 45.04a,b

223.35 ± 32.59a,b

303.41 ± 40.44a

0.79

KIM-1 (ng/mL)

1.46 ± 0.14

1.45 ± 0.12

1.48 ± 0.07

1.62 ± 0.12

0.69

a
a

a

a,b

a,b

a,b

a,b

a,b

a,b

a
a

a

* ANOVA with repeated measures is used for the comparison of each biomarker according to time periods. Paired
t-test with Bonferroni correction was used for multiple comparisons between tests (a > 0.05; b < 0.05).

The serum cystatin C level in neonates is one of the
promising parameters in the diagnosis and follow-up of
AKI. Cystatin levels are not affected by gender, size, or
gestational week and are also independent of body mass
and serum bilirubin levels. Furthermore, fetal cystatin C
levels are not affected by maternal cystatin C levels [12].
In our study, cystatin C values in urine were high in the
CCHD group, and although it was not significant, an
increase in cystatin C was detected in the postoperative
period. Urine cystatin C levels were significantly higher at
24–48 h of life in patients who went on to develop AKI
after the operation. A total of 374 children were included
in a study by Krawczeski et al. [13], and NGAL levels of
urine and serum were examined from 35 newborns ˂ 30
days of life after cardiopulmonary bypass. In this study,
serum cystatin C concentrations increased significantly
in AKI patients 12 h after cardiopulmonary bypass (P <
0.0001) and remained elevated at 24 h (P < 0.0001) [13].
Additionally, Zhang et al. [14] reported that cystatin C is
an excellent predictor of AKI.
The IL-18 level in urine is considered an early
noninvasive biomarker for AKI [15]. Urinary NGAL and
IL-18 in children undergoing cardiac surgery have recently
been shown to be biomarkers revealing AKI. In our study,
urinary IL-18 levels at 24–48 h of life were significantly
higher in patients who went on to develop AKI during
any time period; however, IL-18 could not predict the
inception of AKI in the postoperative period. Li et al. [16]
used new urinary biomarkers to detect AKI in 62 critically
ill neonates (8 with neonatal encephalopathy), and IL-18
levels in urine were significantly higher in critically ill
newborns with nonseptic AKI compared to the control
group [16].
Neutrophil gelatinase-associated lipocalin (NGAL)
is regulated by mRNA induction in cases of infection,
cancer, and renal tubular damage. In cases of renal
epithelial damage, serum NGAL levels increase 7-16–
fold and urinary NGAL levels increase 25-100–fold. In
the pediatric and adult age groups, NGAL levels increase
significantly in patients with AKI, and this increase begins
24–48 h before the elevation of serum creatinine [17]. In
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our study, NGAL levels were lower in the urine during
the preoperative period and increased significantly in the
postoperative period. Oncel et al. [18] reported elevated
urinary NGAL levels during the first day among patients
with perinatal asphyxia. In the study by Tanigasalam et al.
[19], among 120 neonates exposed to perinatal asphyxia,
55 (46%) developed AKI. According to this study, a
NGAL level of 86.82 ng/mL had a sensitivity of 87% and a
specificity of 87.7% to predict AKI.
The KIM-1 molecule is an indicator that is being
studied as an early-period marker of AKI in adults. The
KIM-1 levels in urine can distinguish ischemic kidney
damage according to prerenal azotemia and chronic
kidney disease [20]. Han et al. [21] stated that among 40
patients who underwent cardiac surgery, urinary KIM-1
values were high in 20 patients who were developing AKI.
In our study, the mean KIM-1 levels were higher in the
postoperative period compared to the other periods, and
the 24–48 h KIM-1 levels of the patients who died in this
group were significantly higher.
In conclusion, AKI is commonly seen in NICUs and
results in undesired effects on morbidity and mortality.
Studies of urinary biomarkers are limited in neonates with
CCHD, and to date there is no internationally accepted
biomarker for AKI. According to our results, in newborns
with CCHD, high KIM-1 levels may predict mortality,
whereas high cystatin C (during the first 24–48 h of life)
and preoperative NGAL levels may be indicative of the
postoperative development of AKI. These biomarkers
deserve further investigation in larger study populations.
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Table 3. The levels of urinary biomarkers according to AKI at all time periods.
First 24 h
(AKI n = 0)

24-48th h of life*
(AKI n = 15)
Group 2
(n = 37)

Cystatin C (ng/ml) mean±SD

16.71 *
(16.3-31.01)

16.16 *
0.24 13.89 ± 4.46
(11.95-28.07)

IL-18 (ng/ml) mean ± SD

19.54 ± 5.90

19.18 ± 4.25

0.93 15.01 ± 3.60

NGAL (ng/ml)*
Median (min-max)

382
(28-933)

110.5
(21-621)

0.37

KIM-1 (ng/ml) mean ± SD

1.83 *
(0.36-2.60)

1.63 *
(0.08-2.16)

0.24

Serum creatinine (mg/dl) mean ± SD 0.78 ± 0.30

0.74 ± 0.23

Creatinine clirence mean ± SD

Group 1
(n = 16)

Group 2
(n = 37)

P

20.39 ± 4.29 0.06

15.76 ± 3.12

17.82 ± 9.17

0.59 20.17 ± 2.46 22.12 ± 5.44

0.85

18.98 ± 4.60 0.03

16.34 ± 2.60

18.01 ± 4.88

0.11 19.45 ± 4.34 18.14 ± 6.03

0.20

60.5
(19-417)

65
(15-846)

0.80

80
(19-417)

57
(11-552)

0.26

34.5
(7-452)

286
(12-785)

0.34

1.54 *
(0.06-1.81)

1.69 *
(0.13-2.02)

0.21

1.36 ± 0.70

1.36 ± 0.51

0.71

1.63 *
(1.13-2.09)

1.83 *
(0.32-3.42)

0.96

0.60 0.67 ± 0.36

0.89 ± 0.33

0.06

0.60 ± 0.31

0.67 ± 0.37

0.04 0.55 ± 0.32

0.77 ± 0.40

0.006

P

Group 1
(n = 16)

Group 2
(n = 37)

Postoperative
(AKI n = 27)

P

Group 1
(n = 16)

Group 2
(n = 37)

P

32.67 ± 15.18 32.73 ± 12.34 0.92 47.54 ± 36.06 27.55 ± 10.8 0.005 50.65 ± 35.22 44.55 ± 29.56 0.02 63.0 ± 46.97 37.71 ± 24.22 0.01

*Values are given as median (min-max).
P values are defined using sample t-test and Mann-Whitney U-test.
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Group 1
(n = 16)

Preoperative
(AKI n = 14)
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